To the OMX
Announcement No. 03-08 / Copenhagen, 8 February 2008

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen Ø
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

TopoTarget Clarifies Status of Collaboration with LEO-Pharma, in order to Fully Ensure Accurate and Full Information to the market

Copenhagen, Denmark – February 8, 2008– TopoTarget A/S (OMX: TOPO) today wishes to clarify the status of the company's collaboration with LEO Pharma concerning a pre-clinical compound for investigation for the treatment of psoriasis. The clarification follows the publication of information connected with an interview with LEO Pharma, which appeared in the Danish newspaper Børsen today.

TopoTarget was informed on January 23 2008 that LEO Pharma planned to discontinue development of a very early stage pre-clinical compound originally in-licensed from TopoTarget for the treatment of psoriasis. Under the terms of the agreement the collaboration ends after a three month period on April 30 2008.

During the termination period a report concerning the project will be sent to TopoTarget by LEO Pharma.

TopoTarget wishes to state that information regarding pre-clinical programs with insignificant financial and strategic impact on the company are normally announced in the Quarterly report.

The HDACi (PXD 118490/LEO 80140) pre-clinical compound was out-licensed to LEO Pharma in 2006 for investigation for potential use in treating psoriasis. The compound will now revert to TopoTarget's pre-clinical team where further development opportunities will be consididered. This compound was one out of around 800 compounds in TopoTarget's pre-clinical library.

"Psoriasis is not a focus area for TopoTarget and this out-licensing agreement was part of our business development strategy to allow pharmaceutical companies to investigate interesting compounds in early stage development efforts to find new treatments." Said Peter Buhl Jensen, CEO of TopoTarget. *"TopoTarget is dedicated to finding treatments for cancer and the value of business is in our marketed product Savene®/Totect™ and in our robust clinical pipeline consisting of belinostat and 8 additional products in Phase I and Phase II clinical development."*

Today's news does not change TopoTarget's full-year financial guidance.

TopoTarget A/S

TopoTarget Clarifies Status of Collaboration with LEO-Pharma, in order to Fully Ensure Accurate and Full Information to the market

For further information, please contact:

Peter Buhl Jensen Telephone +45 39 17 83 43
CEO

Background information

About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene®/Totect™ were approved by EMEA in 2006 and the FDA in 2007 and is TopoTarget's first product on the market. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.